146P - Stereotactic ablative radiotherapy (SART) of lung lesion in oligometastatic patients: The importance of high doses delivery

Date 17 April 2015
Event ELCC 2015
Session Poster lunch
Topics Non-Small-Cell Lung Cancer, Locally Advanced
Surgery and/or Radiotherapy of Cancer
Presenter Vieri Scotti
Citation Annals of Oncology (2015) 26 (suppl_1): 45-47. 10.1093/annonc/mdv051
Authors V. Scotti1, I.F. Furfaro1, D. Scartoni1, L. Paoletti2, M. Loi1, S. Russo2, S. Pallotta1, B. Agresti1, P. Bastiani2, L. Livi1
  • 1Radiotherapy Oncology, Azienda Ospedaliera Universitaria Careggi, 50127 - Firenze/IT
  • 2Radiotherapy Oncology, Azienda Sanitaria of Florence, Firenze/IT



The standard treatment of metastatic patients is chemotherapy; in oligomestatic patients (number and sites of metastases limited from one to five) local treatment such as surgery and SART can be considered. Our aim is to evaluate tolerability and outcomes of SART the treatment of patients with malignancies metastatic to the lung.


Seventy-four lung metastases in 61 patients, treated from 2011 to 2014 at University of Florence and Azienda Sanitaria of Florence, were analyzed. The median age was 72 years (range 21-90). Primary lesions included colorectal (n = 20), and non-colorectal lesions (non-small cell lung cancer (n = 15), others histologies, n = 26). All patients had at least stable extra-thoracic disease. In 45 patients metastases were confined to the lung; the number of lung metastases per patient ranged from one to two. In sixteen patients metastases confined to two organs (lung + liver, lung + bone and lung + central nervous system in 9, 5 and 1 patients respectively). Fifty-one and 10 patients showed peripheral and central lesions respectively. The median time of metastases occurrence was 32 months (range 0-204 months). SART was prescribed to a median biological dose equivalent (BED) of 100 Gy (range 20-180 Gy) in a median of three fractions (range 1-5 fractions).


The median follow-up was 12 months (range 1-64 months). The 6, 9 and 12 months actuarial local control rates for all treated lesions were 88%, 81% and 77%, respectively. Seventeen patients had local failure. There were no grade 4 or 5 toxicities; only 6 patients presented grade 3 toxicities (pneumonitis). Statistical analyses showed that age, gender, performance status, previous chemotherapy, median time of metastases occurrence, site of lesions (peripheral versus central) or dimensions had no significant effect on LC rates. The only predictor of better local control on multivariate analysis was a BED value > 100 Gy.


SART for lung metastases achieved excellent local tumour control with low toxicity.


All authors have declared no conflicts of interest.